Unformatted text preview: the first treatment that targets immune cells called CD20-positive B-cells. These B-cells are thought to affect the initiation and development of the disorder. The FDA used a random, double-blind, placebo controlled study to aid in its decision to approve the new antibody. The adverse side affects observed by patients that were exposed to Rituxan for 8 years were said to be similar to patients suffering from non-Hodgkin’s lymphoma. Common side effects noted during the clinical trials consisted of mostly infections and infusion reactions. In conclusion, the new treatment Rituxan is an important treatment to help those suffering from Rheumatoid Arthritis. It seems to safely lower the amount of bad B-cells while leaving the cells one needs such as stem cells and plasma cells unharmed. This new treatment may also help combat other autoimmune diseases in the future....
View Full Document
- Fall '07